Dineen Michael, Hansen Elizabeth, Guancial Elizabeth, Sievert Lynn, Sahasrabudhe Deepak
1 Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY, USA.
2 University of Rochester Medical Center, Rochester, NY, USA.
J Oncol Pharm Pract. 2018 Jun;24(4):314-318. doi: 10.1177/1078155217701294. Epub 2017 Mar 29.
Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
阿比特龙是一种细胞色素P450 17α酶（CYP17）抑制剂，可阻断多种组织类型中的雄激素生物合成。与泼尼松联合使用时，它被批准作为转移性去势抵抗性前列腺癌的一线治疗药物。我们报告了1例转移性去势抵抗性前列腺癌患者在接受阿比特龙治疗时发生横纹肌溶解症，进而导致急性慢性肾损伤的病例。对于开始使用阿比特龙且有发生横纹肌溶解症其他危险因素的患者，应进行严格监测。
